Outlook Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended March 31, 2021. The company is a late clinical-stage biopharmaceutical developer focused on ONS-5010 (LYTENAVA), an investigational ophthalmic bevacizumab formulation. It had no approved products and generated no product-sales revenue.
Financial position and results
| Metric | Three months ended March 31, 2021 | Six months ended March 31, 2021 |
|---|---|---|
| Revenue | No product-sales revenue | No product-sales revenue |
| Research and development expense | $8.5 million | $20.5 million |
| General and administrative expense | $4.1 million | $6.3 million |
| Net loss | $13.1 million | $27.6 million |
| Net loss per share, basic and diluted | $0.09 | $0.20 |
| Net cash used in operating activities | $25.1 million for the six-month period |
- Cash was $37.2 million at March 31, 2021, versus $12.5 million at September 30, 2020. Management estimated available cash would fund operations through November 2021.
- Total liabilities were $24.5 million. Debt included approximately $10.5 million of principal and accrued interest under an unsecured note due January 1, 2022, and a $0.9 million PPP loan due May 2022.
- Cash provided by financing activities was $49.7 million, mainly from approximately $39.8 million of net equity proceeds, $10.0 million of note proceeds, and $3.6 million from warrant exercises, partly offset by debt and lease repayments.
- There are no meaningful operating margins to report because the company had no product revenue.
Changes versus prior-year periods
- Quarterly operating expenses increased to $12.6 million from $6.8 million; six-month operating expenses rose to $26.8 million from $14.9 million. The increases were driven chiefly by ONS-5010 development, clinical work, and manufacturing scale-up.
- Quarterly net loss increased to $13.1 million from $5.7 million. Six-month net loss rose to $27.6 million from $22.3 million, although the 2020 comparison included an $8.1 million debt-extinguishment loss and other noncash or preferred-stock-related items.
- Operating cash use increased to $25.1 million from $13.8 million for the six-month periods, reflecting increased development spending.
- Common shares outstanding increased to 173.6 million from 127.2 million at September 30, 2020, including shares issued in the February 2021 financing and warrant exercises.
Outlook, risks and notable items
- Going concern: The filing states that recurring losses, negative operating cash flows, and debt obligations raise substantial doubt about the company’s ability to continue as a going concern. Additional financing is required, and success is not assured. The company may need to reduce or defer programs, cut staff, liquidate assets, or seek bankruptcy protection if funding is unavailable.
- Clinical and regulatory outlook: NORSE TWO, the pivotal Phase 3 wet AMD trial, had completed enrollment; topline results were expected in the third calendar quarter of 2021. Management planned a wet AMD BLA submission in the first quarter of 2022, subject to trial results and other requirements. The company intended to start NORSE FOUR, NORSE FIVE, and NORSE SIX in 2021, after NORSE TWO completion.
- Funding and dilution: The company completed a February 2021 public offering and concurrent private placements and entered an at-the-market offering agreement in March. Future equity financing may dilute existing holders; debt or partnership financing may not be available on acceptable terms.
- Litigation settlement: A confidential settlement resolved Liomont’s contract claim, which had sought $3.0 million. The company recorded and paid a $625,000 initial settlement amount in April 2021; a further $750,000 is contingent on specified future events.
- China joint venture: Formed in April 2021, the venture is 80% owned by Syntone’s PRC affiliate and 20% by Outlook. Outlook licensed ONS-5010 royalty-free for the greater China market and expects an additional capital contribution of approximately $2.1 million within four years.
- COVID-19: Management reported limited disruption to date and no significant impact on the six-month financial results, but cautioned that future effects on trial timelines and operations remain uncertain.
- Other items: The company assigned its Monmouth Junction lease and reported no remaining obligations under it at March 31, 2021; a new three-year Iselin office lease commenced April 23, 2021, with minimum payments totaling $135,535. Management said disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether NORSE TWO results support the expected BLA filing timetable and whether regulators require additional data or work.
- Whether new financing, licensing, or commercial partnerships are secured before the stated cash runway ends, and the resulting dilution or debt terms.
- The unsecured note’s amount due and repayment capacity by its January 2022 maturity, including its default provisions.
- The status and cost of the contingent Liomont settlement payment and the PRC joint venture’s planned additional capital contribution.
- Whether clinical, manufacturing, regulatory, competitive, or COVID-19 developments materially affect ONS-5010 timelines, costs, or prospects for approval and market acceptance.